ArticleEuropean geriatric medicine2026
Age-based analysis of the SEC-Excelente-HF registry: clinical characteristics and prognosis of a prospective cohort of heart failure patients.
Article in European geriatric medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeart failure (HF) is highly prevalent in older adults with multiple comorbidities and geriatric syndromes, yet evidence on their management in structured HF units is limited. We assessed the clinical profile, treatment, and outcomes of older HF patients managed in accredited units in Spain.
methodsThe SEC-Excelente-HF registry prospectively included 2,245 consecutive patients from 68 accredited HF units (2019-2023). Patients were stratified by age (< 75 years, n = 1267; ≥ 75 years, n = 973). Both hospitalized and outpatient patients were followed for 1 year. Data on demographics, comorbidities, therapies, and devices were collected. Primary outcomes were all-cause mortality, HF hospitalization, and their composite. Multivariable Cox models identified independent predictors of outcomes by age group.
resultsMedian age was 73 years, and 43.4% were ≥ 75 years. Older patients had higher prevalences of atrial fibrillation, valvular heart disease, chronic kidney disease, and anemia (all p < 0.001). Use of guideline-directed medical therapy was consistently lower in older patients, including RAAS inhibitors (69.2% vs 81.1%), beta-blockers (73.8% vs 87.1%), MRAs (46.2% vs 70.5%), and SGLT2 inhibitors (42.0% vs 62.4%; all p < 0.001). At 1 year, event-free survival was 66.3% in older vs 77.0% in younger patients (p < 0.001). In older patients, independent predictors of the composite outcome included prior HF, anemia, malnutrition, functional disability, advanced chronic kidney disease, and CRT/ICD implantation.
conclusionsDespite specialized care, older HF patients in accredited units exhibit a higher comorbidity burden, lower use of evidence-based therapies, and worse outcomes than younger patients. Enhanced multidisciplinary strategies are needed to improve prognosis in this growing population.
Indexed as
Identifiers
41442098What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.